A Randomized Controlled Trial Comparing Glargine U300 and Glargine U100 for the Inpatient Management of Medicine and Surgery Patients With Type 2 Diabetes: Glargine U300 Hospital Trial
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The role of U300 glargine insulin for the inpatient management of type 2 diabetes (T2D) has not been determined. We compared the safety and efficacy of glargine U300 versus glargine U100 in noncritically ill patients with T2D. RESEARCH DESIGN AND METHODS: This prospective, open-label, randomized clinical trial included 176 patients with poorly controlled T2D (admission blood glucose [BG] 228 ± 82 mg/dL and HbA1c 9.5 ± 2.2%), treated with oral agents or insulin before admission. Patients were treated with a basal-bolus regimen with glargine U300 (n = 92) or glargine U100 (n = 84) and glulisine before meals. We adjusted insulin daily to a target BG of 70–180 mg/dL. The primary end point was noninferiority in the mean difference in daily BG between groups. The major safety outcome was the occurrence of hypoglycemia. RESULTS: There were no differences between glargine U300 and U100 in mean daily BG (186 ± 40 vs. 184 ± 46 mg/dL, P = 0.62), percentage of readings within target BG of 70–180 mg/dL (50 ± 27% vs. 55 ± 29%, P = 0.3), length of stay (median [IQR] 6.0 [4.0, 8.0] vs. 4.0 [3.0, 7.0] days, P = 0.06), hospital complications (6.5% vs. 11%, P = 0.42), or insulin total daily dose (0.43 ± 0.21 vs. 0.42 ± 0.20 units/kg/day, P = 0.74). There were no differences in the proportion of patients with BG <70 mg/dL (8.7% vs. 9.5%, P > 0.99), but glargine U300 resulted in significantly lower rates of clinically significant hypoglycemia (<54 mg/dL) compared with glargine U100 (0% vs. 6.0%, P = 0.023). CONCLUSIONS: Hospital treatment with glargine U300 resulted in similar glycemic control compared with glargine U100 and may be associated with a lower incidence of clinically significant hypoglycemia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“RCTs have shown that treatment with a basal prandial regimen using insulin analogs improved glycemic control with fewer hospital complications in general medical and surgical persons with T2D compared with sliding-scale regular insulin alone.92,107,108,1333–1336”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1335]
In the citing paper
“Data on the use of concentrated insulins such as glargine U-300, degludec U-200, and U-500 regular insulin in the inpatient and perioperative settings are limited and have shown variable results (78-81).”
From 16. Diabetes Care in the Hospital: Standards of Care in Diabetes—2026 (2026) · cites this paper as [79]
Citations
Cites
Battelino, T., Danne, T., Bergenstal, R. M., Amiel, S. A., Beck, R., Biester, T., Bosi, E., Buckingham, B. A., Cefalu, W. T., Close, K. L., et al. (2019) · Diabetes Care · doi:10.2337/dci19-0028 · Cited by 4,237 · cited 1×
“In addition, glucose values obtained with CGMwere analyzed to compare the percentage of time that the sensor glucose measurement was below the target range (54–69mg/dL and,54mg/dL) (23).”
MethodStandards of Medical Care in Diabetes—2012
(2012) · Diabetes Care · doi:10.2337/dc12-s011 · Cited by 2,240
Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes
Umpierrez, G. E., Isaacs, S. D., Bazargan, N., You, X., Thaler, L. M., & Kitabchi, A. E. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.3.8341 · Cited by 2,195
Self-citationMalmberg, K., Rydén, L., Efendic, S., Herlitz, J., Nicol, P., Waldenstrom, A., Wedel, H., & Welin, L. (1995) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(95)00126-k · Cited by 1,560
Van den Berghe, G., Wouters, P. J., Bouillon, R., Weekers, F., Verwaest, C., Schetz, M., Vlasselaers, D., Ferdinande, P., & Lauwers, P. (2003) · Critical Care Medicine · doi:10.1097/01.ccm.0000045568.12881.10 · Cited by 1,455
Moghissi, E. S., Korytkowski, M. T., DiNardo, M., Einhorn, D., Hellman, R., Hirsch, I. B., Inzucchi, S. E., Ismail-Beigi, F., Kirkman, M. S., & Umpierrez, G. E. (2009) · Diabetes Care · doi:10.2337/dc09-9029 · Cited by 1,444
Self-citationUmpierrez, G. E., Hellman, R., Korytkowski, M. T., Kosiborod, M., Maynard, G. A., Montori, V. M., Seley, J. J., & Van den Berghe, G. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2098 · Cited by 1,126
Self-citationGlucose Control and Mortality in Critically Ill Patients
Finney, S. J. (2003) · JAMA · doi:10.1001/jama.290.15.2041 · Cited by 1,055
Umpierrez, G. E., Smiley, D., Jacobs, S., Peng, L., Temponi, A., Mulligan, P., Umpierrez, D., Newton, C., Olson, D., & Rizzo, M. (2011) · Diabetes Care · doi:10.2337/dc10-1407 · Cited by 720 · cited 6×
“The results of multiple clinical trials in the hospital setting suggest that patients with diabetes may respond differently to a commonly used basal-bolus approach (7,9,12,24,25,29).”
BackgroundMethodResultInfluentialSelf-citationEarly Postoperative Glucose Control Predicts Nosocomial Infection Rate in Diabetic Patients
Pomposelli, J. J., Baxter, J. K., Babineau, T. J., Pomfret, E. A., Driscoll, D. F., Forse, R. A., & Bistrian, B. R. (1998) · Journal of Parenteral and Enteral Nutrition · doi:10.1177/014860719802200277 · Cited by 700
Cited by
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Self-citationManagement of diabetes and hyperglycaemia in the hospital
Pasquel, F. J., Lansang, M. C., Dhatariya, K., & Umpierrez, G. E. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30381-8 · Cited by 329
Self-citation16. Diabetes Care in the Hospital: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s016 · Cited by 195
Self-citation16. Diabetes Care in the Hospital: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Galindo, R. J., Hilliard, M. E., Johnson, E. L., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s016 · Cited by 167
Self-citationGalindo, R. J., Aleppo, G., Klonoff, D. C., Spanakis, E. K., Agarwal, S., Vellanki, P., Olson, D. E., Umpierrez, G. E., Davis, G. M., & Pasquel, F. J. (2020) · Journal of Diabetes Science and Technology · doi:10.1177/1932296820932903 · Cited by 155
Self-citation16. Diabetes Care in the Hospital: Standards of Care in Diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s016 · Cited by 80
Rosenstock, J., Juneja, R., Beals, J. M., Moyers, J. S., Ilag, L. L., & McCrimmon, R. J. (2024) · Endocrine Reviews · doi:10.1210/endrev/bnad037 · Cited by 92
“This advance was considered a clinically significant improvement over IGlar U100, again by contributing to lower glycemic variability and lower hypoglycemia risk compared to IGlar U100 (15, 16).”
Concentrated insulins: Clinical update of therapeutic options
Umpierrez, G. E., Holt, E. H., Einhorn, D., & McGill, J. B. (2020) · Endocrine Practice · doi:10.4158/ep-2019-0607 · Cited by 44
Self-citationGalindo, R. J., Pasquel, F. J., Vellanki, P., Alicic, R., Lam, D. W., Fayfman, M., Migdal, A. L., Davis, G. M., Cardona, S., Urrutia, M. A., et al. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14544 · Cited by 26
“0 mmol/L.(26) The present study builds on the information available on the efficacy and safety of a basal-bolus regimen with the use of”
Self-citationPerioperative glycaemic control for people with diabetes undergoing surgery
Bellon, F., Solà, I., Giménez‐Pérez, G., Hernández, M., Metzendorf, M., Rubinat, E., & Mauricio, D. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007315.pub3 · Cited by 48
Inpatient Hyperglycemia Management and COVID-19
Bellido, V., & Pérez, A. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00966-z · Cited by 27
“This study also demonstrates that therapy intensification at discharge with glargine U300 is an effective strategy, improving HbA1c by 1.6% at months 3 and 6 post discharge with an adequate safety profile and a high degree of treatment satisfaction [57].”
BackgroundInfluentialCheng, A. Y. Y., Wong, J., Freemantle, N., Acharya, S. H., & Ekinci, E. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00925-8 · Cited by 20
Advances in the management of hyperglycaemia and diabetes mellitus during hospitalization
Idrees, T., Castro-Revoredo, I., Dhatariya, K., Hernandez, L., & Umpierrez, G. E. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01157-1 · Cited by 25
“Several studies have demonstrated that the basal–bolus approach is effective and safe for managing most people with T2DM in general surgery or medical settings 58–60 .”
Self-citationIdrees, T., Zabala, Z. E., Moreno, E. M., Gerges, A., Urrutia, M. A., Ruíz, J. G., Vaughan, C. P., Vellanki, P., Pasquel, F. J., Peng, L., et al. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110603 · Cited by 10
Self-citationD’Souza, S., & Kruger, D. F. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00920-z · Cited by 7
“The largest study with published findings so far is the glargine U300 hospital trial [54], in which 176 patients with poorly controlled T2D were randomized to receive a basal–bolus regimen with either glargine U300 or glargine U100 and insulin glulisine before meals after admission to hospital.”
BackgroundEvidence-based therapeutics for hyperglycemia in hospitalized noncritically ill patients
Gracia‐Ramos, A. E., Carretero‐Gómez, J., Mendez, C. E., & Carrasco-Sánchez, F. J. (2021) · Current Medical Research and Opinion · doi:10.1080/03007995.2021.1997288 · Cited by 7
“A randomized controlled trial (RCT) conducted by Pasquel et al.35 compared iGla U300 and iGla U100 in noncritical medical and surgical inpatients with T2D.”
MethodInfluentialMarino, E. C., Momesso, D., Toyoshima, M. T. K., de Almeida, M. F. O., Schaan, B. D., Negretto, L. A. F., Junior, A. C. S., Cukier, P., Genestreti, P., Feitosa, A. C. R., et al. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01585-z · Cited by 10
Development of insulin and its pharmacology and perioperative use: a narrative review
Dhatariya, K., Levy, N., Stubbs, D. J., Frank, C., Tinsley, S. L., & Knaggs, R. (2025) · British Journal of Anaesthesia · doi:10.1016/j.bja.2025.05.006 · Cited by 8
An Overview of Currently Available Injectable Therapies in Diabetes: A Guide to Practitioners
Kesavadev, J., Basanth, A., Shankar, A., Saboo, B., Mohan, A. R., Joshi, S., Ghosh, S., Krishnan, G., Jothydev, K., & Ashik, A. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03250-3 · Cited by 8
“After this period, any remaining insulin should be discarded to ensure potency and effectiveness [22, 23].”
Gracia‐Ramos, A. E., Cruz-Domínguez, M. P., & Madrigal‐Santillán, E. (2021) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2021.09.003 · Cited by 3
Kuchay, M. S., Mathew, A., Mishra, M., Surendran, P., Kaur, P., Wasir, J. S., Gill, H. K., Jain, R., Gagneja, S., Kohli, C., et al. (2022) · Diabetic Medicine · doi:10.1111/dme.15002 · Cited by 3
Wulfe, S., Janzen, K. M., Addison, J. D., & Kelley, D. (2022) · Annals of Pharmacotherapy · doi:10.1177/10600280221119187 · Cited by 2
“033 Time to hypoglycemic events, hr (median, IQR) 10 (8-14) 18 (10-33) 0.”
Gracia‐Ramos, A. E., Cruz-Domínguez, M. P., Madrigal‐Santillán, E., Rojas-Martínez, R., Morales‐González, J. A., Morales‐González, Á., Hernández-Espinoza, M., Vargas-Peñafiel, J., & Tapia-González, M. D. L. Á. (2024) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2024.108742 · Cited by 2
Ketaroonrut, N., Kiertiburanakul, S., & Sriphrapradang, C. (2024) · SAGE Open Medicine · doi:10.1177/20503121241238148 · Cited by 3
“44,46 The primary end point was to assess the differences in glycemic control between treatment groups, measured by the treatment failure rates.”
BackgroundIn-Hospital Management of Hyperglycemia: The Role of Insulin Degludec
WANGNOO, S. K., Baruah, M. P., Lodha, S., Sanyal, D., Goyal, R., Sooragonda, B. G., Chandrasekaran, S., & Kumar, G. V. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01707-w · Cited by 2
Soliman, D., Varghese, R. T., Umpierrez, G. E., & Galindo, R. J. (2025) · Medical Clinics of North America · doi:10.1016/j.mcna.2025.11.006 · Cited by 1
Self-citationUso inicial de insulina en pacientes hospitalizados con diabetes mellitus tipo 2
Díaz, J. J. S., Arias, L. O. M., Murcia, A. M. P., Díaz, A. L. A., Ângulo, P. S., Roa, D. E. M., & Orjuela, A. M. (2022) · Revista Colombiana de Endocrinología Diabetes & Metabolismo · doi:10.53853/encr.8.4.714 · Cited by 1
Li, X., He, A., Liu, B., Shan, R., Zhu, J., Li, X., Xie, T., Li, Y., Chen, M., Su, H., et al. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1407829 · Cited by 1
Henao, D. C., Gómez, A. M., Robledo, S., & Rosero, R. (2025) · Mini-invasive Surgery · doi:10.20517/2574-1225.2024.106 · Cited by 1
Gracia‐Ramos, A. E., Cruz-Domínguez, M. P., & Madrigal‐Santillán, E. (2021) · Revista Clínica Española · doi:10.1016/j.rce.2021.09.002
Insulin Glargin U300 bewährt sich im stationären Setting
(2020) · Diabetologie und Stoffwechsel · doi:10.1055/a-1213-3889
Zheng, M., Khoja, A. A., Patel, A., Luo, Y., He, Q., Zhao, X., Yang, S., Hu, P., & Lin, W. (2022) · Systematic Reviews · doi:10.1186/s13643-022-01986-5
“Especially in the past decade, many RCTs have used CGM as an assessment tool to monitor real-time glycaemic changes of oral ADM with excellent feasibility and precision [11, 13, 14].”
BackgroundInpatient Precision Medicine for Diabetes
Davis, G. M., Umpierrez, G. E., & Pasquel, F. J. (2022) · Springer eBooks · doi:10.1007/978-3-030-98927-9_9
Self-citationChawla, M. S., CHAWLA, P. M., Saboo, B., Kesavadev, J., Gupta, A., & Parikh, R. M. (2022) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_12_22 · Cited by 1
de Souza, A. B. C. (2022) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2022.tde-17042023-113357 · Cited by 1
Repetto, P., & Ayago, D. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108584
Zhang, X., Yan, D., Du, T., Zhao, Y., Zhang, J., Zhang, T., Lin, M., Li, Y., & Li, W. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01193-9 · Cited by 1
“At the end of the corresponding clinical trials, Umpierrez found that the ratio of basal-bolus was about 1:1 in their two clinical trials (glargine to glulisine, 22:20 units/day and 43:42 units/day) and Meyer et al. found the ratio as about 1:1 (glargine to glulisine 33:36 units/day) [13–15].”
BackgroundAlexanian, S. M., Cheney, M. C., Spartano, N. L., Bello-Ramos, J. C., Reddy, N., Malik, A., Murati, J., Wolpert, H. A., & Steenkamp, D. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.11.015
Zheng, M., Khoja, A., Patel, A., Luo, Y., He, Q., Zhao, X., Yang, S., Hu, P., & Lin, W. (2022) · Figshare · doi:10.6084/m9.figshare.19977306
Zheng, M., Khoja, A., Patel, A., Luo, Y., He, Q., Zhao, X., Yang, S., Hu, P., & Lin, W. (2022) · Figshare · doi:10.6084/m9.figshare.19977300
Zheng, M., Khoja, A., Patel, A., Luo, Y., He, Q., Zhao, X., Yang, S., Hu, P., & Lin, W. (2022) · Figshare · doi:10.6084/m9.figshare.19977303
Zheng, M., Khoja, A., Patel, A., Luo, Y., He, Q., Zhao, X., Yang, S., Hu, P., & Lin, W. (2022) · Figshare · doi:10.6084/m9.figshare.19977297
Passarella, P., & Gosmanov, A. R. (2025) · Medical Clinics of North America · doi:10.1016/j.mcna.2025.11.001 · Cited by 1
Stress-Induced Hyperglycemia in General Surgery
Zaino, J., Diaz-Sarmiento, V. S., Idrees, T., & Umpierrez, G. E. (2026) · Clinics in Perioperative Nursing Care · doi:10.1016/j.pernc.2026.05.005
Self-citationThe Use of Diabetes Technology in the Inpatient Setting
Akcan, T., Faulds, E. R., Lal, R., Davis, G. M., Brown, S. A., Pasquel, F. J., & Hughes, M. S. (2026) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2026.08.016
Self-citation
Metadata
- Authors
- Pasquel, F. J., Lansang, M. C., Khowaja, A., Urrutia, M. A., Cardona, S., Albury, B., Galindo, R. J., Fayfman, M., Davis, G., Migdal, A., Vellanki, P., Peng, L., & Umpierrez, G. E.
- Affiliations
- Emory University (US)
- Cleveland Clinic (US)
- University of Minnesota (US)
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2020-04-09
- Volume
- 43
- Issue
- 6
- Pages
- 1242-1248
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC7411278
- OpenAlex
- W3015651592
- Cited by
- 45
- References
- 37
- Citations by year
- 2026: 2 · 2025: 9 · 2024: 6 · 2023: 5 · 2022: 12 · 2021: 5 · 2020: 6
- FWCI
- 5.28
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Sanofi
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- long-acting insulin, inpatient diabetes management, multiple daily insulin injections, glulisine, hypoglycemia, glycemic control, non-inferiority, length of hospital stay, in-hospital complications, insulin dose reduction, non-critically ill patients, uncontrolled diabetes
- MeSH terms
- Insulin Glargine, Equivalence Trials as Topic, Adult, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Female, Hospitalization, Humans, Hypoglycemia, Hypoglycemic Agents, Inpatients, Internal Medicine, Male, Middle Aged, Minnesota, Surgery Department, Hospital
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.